The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 10, 2018

Filed:

Dec. 10, 2015
Applicants:

Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;

Universite Paris-sud, Orsay, FR;

Institut Gustave Roussy, Villejuif, FR;

Universite Paris Descartes, Paris, FR;

Universite Pierre ET Marie Curie (Paris 6), Paris, FR;

Institut Pasteur, Paris, FR;

Istituto Nazionale Per Le Malattie Infettive Irccs Lazzaro Spallanzani, Rome, IT;

Assistance Publique-hopitaux DE Paris (Aphp), Paris, FR;

Inventors:

Guido Kroemer, Paris, FR;

Jean-Luc Perfettini, Villejuif, FR;

Marie-Lise Gougeon, Paris, FR;

Awatef Allouch, Villejuif, FR;

Mauro Piacentini, Rome, IT;

Attorney:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 45/06 (2006.01); A61K 31/683 (2006.01); A61K 31/5517 (2006.01); A61K 31/165 (2006.01); A61K 31/395 (2006.01); A61K 31/17 (2006.01); A61K 31/713 (2006.01); C12Q 1/18 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/165 (2013.01); A61K 31/17 (2013.01); A61K 31/395 (2013.01); A61K 31/5517 (2013.01); A61K 31/683 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); C12Q 1/18 (2013.01); C12N 2310/14 (2013.01); C12N 2320/31 (2013.01);
Abstract

The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.


Find Patent Forward Citations

Loading…